1-甲基-5-苯基-1H-咪唑-2-硫醇 | 25433-13-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 1-甲基-5-苯基-1H-咪唑-2-硫醇
• 英文名称: 4-phenyl-3-methyl-1,3-imidazole-2-thione
• 英文别名: 1-Methyl-5-phenyl-2(3H)-imidazolethione；1-methyl-5-phenyl-imidazoline-2-thione；phenylmethimazole；1-methyl-5-phenyl-1,3-dihydro-imidazole-2-thione；3-methyl-4-phenyl-1H-imidazole-2-thione；5-phenylmethimazole；1-methyl-5-phenyl-1H-imidazole-2-thiol
• CAS: 25433-13-0
• 化学式: C₁₀H₁₀N₂S
• mdl: MFCD01429053
• 分子量: 190.269
• InChiKey: XGMUOBZHQAVQNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.1
• 拓扑面积：
  47.4
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2933290090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-Methyl-5-phenyl-1h-imidazole-2-thiol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-Methyl-5-phenyl-1h-imidazole-2-thiol
CAS number: 25433-13-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C10H10N2S
Molecular weight: 190.3

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides, sulfur oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  4-(2-氯乙基)咪唑 、 1-甲基-5-苯基-1H-咪唑-2-硫醇 在 sodium ethanolate 作用下， 以 二甲基亚砜 为溶剂， 反应 72.0h， 生成 2-[2-(1H-imidazol-5-yl)ethylsulfanyl]-1-methyl-5-phenylimidazole
  参考文献：
  名称：

  HB-供体基团在H3-拮抗剂的杂环极性片段中的作用。I.合成和生物学测定。

  摘要：

  最近有报道说，由咪唑组成的化合物通过烷基间隔基与2-氨基苯并咪唑连接，对H（3）-受体表现出高亲和力。2-氨基苯并咪唑的胍片段可能与结合位点的氢键相互作用有关，被称为“极性片段”。在目前的工作中，我们从具有二亚甲基间隔基1（pK（i）= 7.25）或三亚甲基1 2（pK（i）= 8.90）的2-氨基苯并咪唑衍生物开始，我们研究了氢键的重要性（HB）供体基团在与H（3）-受体相互作用的极性片段上。用不同的部分取代2-氨基苯并咪唑[2-氨基苯并噻唑，3，4; 2-硫代苯并咪唑，5，6; 2-硫代苯并噻唑，7，8; 2-硫基-4-苯基或2-硫基-5-苯基-N-甲基咪唑，[9-12]强调了极性基团碱性对烷基链最佳长度的影响：较长的间隔基优选具有中等碱性的极性基团，而在存在中性极性基团的情况下，采用亚甲基链。此外，对于具有不同间隔长度的化合物，在2-氨基苯并咪唑部分13-16处的N-甲基化显示出不同

  DOI：

  10.1016/s0014-827x(03)00147-2
• 作为产物：
  描述：

  2-methylaminophenylacetaldehyde diethylacetal 在 盐酸 、 sodium carbonate 、 sodium chloride 作用下， 以 乙醇 、 水 、 乙酸乙酯 为溶剂， 生成 1-甲基-5-苯基-1H-咪唑-2-硫醇
  参考文献：
  名称：

  Methimazole derivatives and tautomeric cyclic thiones to treat autoimmune diseases

  摘要：

  本发明提供了一种治疗哺乳动物自身免疫疾病以及预防或治疗移植受体的移植排斥的方法。这些方法利用特定定义的甲巯咪唑衍生物和互变环硫醇化合物，以及含有这些化合物的药物组合物。已发现这些化合物和组合物在药物活性方面至少与甲巯咪唑同样有效，同时对甲状腺功能的不良影响更小。它们在常规药物载体中的溶解度也比甲巯咪唑更高。还教授了一种用于筛选对自身免疫疾病有用的化合物活性（抑制MHC I和II分子表达能力）的检测方法。

  公开号：

  US06365616B1

文献信息

• Imidazole compounds and their use as transglutaminase inhibitors
  申请人：Merck & Co., Inc.

  公开号：US05030644A1

  公开（公告）日：1991-07-09

  Imidazole compounds including imidazoles and imidazolium salts, and their use as transglutaminase inhibitors are disclosed.

  咪唑化合物，包括咪唑和咪唑盐，以及它们作为转谷氨酰胺酶抑制剂的用途被披露。
• Reducing Platelet Activation, Aggregation and Platelet-Stimulated Thrombosis or Blood Coagulation by Reducing Mitochondrial Respiration
  申请人：Collman James P.

  公开号：US20110301180A1

  公开（公告）日：2011-12-08

  It has been discovered that inhibiting mitochondrial respiration in platelets reduces platelet activation or platelet aggregation. Certain heterocyclic compounds significantly reduced one or more platelet functions including clumping, sticking or platelet-stimulated clotting. Thus diseases or disorders mediated by inappropriately high levels of platelet activation or platelet aggregation can be treated by administering a therapeutically effective amount of a heterocyclic compound or nonheterocyclic mitochondrial inhibitor that significantly reduces one or more platelet functions including clumping, sticking or platelet-stimulated clotting, preferably in a reversible manner.

  已经发现，在血小板中抑制线粒体呼吸可以减少血小板的激活或血小板聚集。某些杂环化合物显著降低了一个或多个血小板功能，包括凝聚、粘附或血小板刺激的凝血。因此，由血小板激活或血小板聚集水平不当高导致的疾病或疾病可以通过给予一种治疗有效量的杂环化合物或非杂环线粒体抑制剂来治疗，该化合物显著降低了一个或多个血小板功能，包括凝聚、粘附或血小板刺激的凝血，最好是以可逆的方式。
• [EN] METHODS AND COMPOSITIONS TO MODIFY GSK-3 ACTIVITY<br/>[FR] PROCÉDÉS ET COMPOSITIONS POUR MODIFIER L'ACTIVITÉ DE GSK-3
  申请人：UNIV OHIO

  公开号：WO2016010611A1

  公开（公告）日：2016-01-21

  Methods for modulating GSK-3 activity and methods for treating a GSK-3 -mediated disorder in a subject in need thereof. The methods include contacting a cell expressing GSK-3 with or administering to the subject in need a therapeutically effective amount of one or more compounds of General Formula (I) or General Formula (II): or pharmaceutically-acceptable salts or solvates thereof.

  调节GSK-3活性的方法和治疗需要的主体中GSK-3介导的疾病的方法。该方法包括将表达GSK-3的细胞与或向需要的主体施用一种或多种通用式(I)或通用式(II)的化合物的治疗有效量接触，或其药用接受的盐或溶剂。
• [EN] NOVEL GUANIDINE MIMICS AS FACTOR Xa INHIBITORS<br/>[FR] NOUVEAUX IMITATEURS DE GUANIDINE UTILISES EN TANT QU'INHIBITEURS DU FACTEUR Xa
  申请人：DU PONT PHARMACEUTICALS COMPANY

  公开号：WO1998057951A1

  公开（公告）日：1998-12-23

  (EN) The present application describes nitrogen containing heteroaromatics and derivatives thereof of formula (I) or pharmaceutically acceptable salt forms thereof, wherein rings D-E represent guanidine mimics, which are useful as inhibitors of factor Xa.(FR) Cette invention concerne des composés hétéroaromatiques contenant de l'azote et des dérivés de ces derniers de formule (I) ou des formes de sel pharmaceutiquement acceptables de ces derniers. Dans la formule les cycles D-E représentent des imitateurs de guanidine qui sont utiles en tant qu'inhibiteurs du facteur Xa.

  本申请描述了含氮杂环和其衍生物的化合物，其化学式为（I）或其药学上可接受的盐形式，其中环D-E代表胍基模拟物，可用作因子Xa的抑制剂。
• Compounds for modulating TRPV3 function
  申请人：Chong A. Jayhong

  公开号：US20070213321A1

  公开（公告）日：2007-09-13

  The present application relates to compounds and methods for treating pain and other conditions related to TRPV3.

  本申请涉及化合物和治疗疼痛和与TRPV3相关的其他病症的方法。